About

Aarti Pharmalabs Limited manufactures pharmaceutical products in India's healthcare sector with a market capitalization of ₹7,720.38 Cr. Recent quarterly revenues range from ₹417 Cr to ₹582 Cr, with significant variation reflecting market and operational conditions.

Face value: ₹5

Market cap

₹8,784 Cr

P/E

41.4×

P/B

4.1×

Dividend yield

0.4%

ROE

8.4%

ROCE

11.5%

Debt / equity

0.32

OPM

20.3%

EPS (TTM)

₹23.4

Book value

₹234.3

52-week high

₹972.8

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Valuation elevated at PE 36.38 relative to modest ROE of 8.4% and weak 1-year returns of 1.64%; verify earnings growth expectations justifying the multiple
Quarterly operating margins swing 17.73%–25.48% and EPS ranges ₹3.08–₹8.4; identify root causes and whether volatility reflects execution risk or fundamental business instability
Pharmaceutical sector faces generic competition and pricing pressure; verify company's product diversification, patent coverage, and ability to defend margins

Generated analysis · source review pending

Growth drivers

Operating margins reached 25.48% in Jun 2026 vs 17.73% in Sep 2025; verify what product mix or cost changes enable higher-margin periods and sustainability
Revenue recovered to ₹534–535 Cr (Jun 2026) from ₹417–418 Cr (Sep 2025); verify if this reflects sustained stabilization or cyclical improvement
Regular dividend payments across 2024–2026 indicate stable cash generation; verify whether reinvestment in R&D or manufacturing capacity supports organic growth
Pharmaceuticals sector typically offers structural growth from healthcare demand; verify company's therapeutic focus, market penetration in high-growth areas, and competitive positioning

Generated analysis · source review pending

₹968.5+17.5%1Y

Beta

0.81

Moves with the index

Volatility (1y)

44.4%

Annualised, daily returns

RSI (14)

71.5

Overbought territory

Rel. strength (1y)

6.1%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Healthy operating margin of 20.3%

Cons

−Profit declined 3.7% a year over the last 3 years
−Revenue shrank over the last 3 years (-2.2% a year)

Research score

Structured signal from quality, growth, valuation and momentum.

52/100

Business quality: 41
Growth: 50
Valuation: 41
Momentum

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,200	1,945	1,853	2,115	1,819
COGS	725	1,170	1,021	1,128	835
Gross profit	475	775	832	987	985
	310	433	446	523	607
	165	342	386	464	377
OPM %	13.7%	17.6%	20.8%	22%	20.7%
Depreciation	—	63	73	87	104
Interest	12	21	17	27	47
	3	2	5	10	7
Profit before tax	155	261	300	361	233
Tax	33	67	84	88	58
Tax %	21.3%	25.8%	27.8%	24.5%	25%
	122	193	217	272	175
PAT margin %	10.2%	10%	11.7%	12.9%	9.6%
EPS (₹)	13.5	21.4	23.9	30.1	19.3
EPS adjusted (₹)	—	21.4	23.9	30.1	19.1
	0%	0%	12.5%	16.6%	18.2%
Annual report	—	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	45	45	45	45
Reserves	1,513	1,712	1,945	2,079
	214	264	396	686
	458	561	520	671
Total equity & liabilities	2,231	2,582	2,906	3,482
	926	1,033	1,137	1,372
CWIP	62	79	307	305
Investments	74	107	77	259
	1,169	1,363	1,386	1,545
Total assets	2,231	2,582	2,906	3,482

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-44	263	216	332	262
	-139	-158	-215	-414	-431
	260	-163	10	65	171
Net cash flow	78	-58	12	-17	2
Free cash flow	—	143	61	-70	-147
CFO / Operating profit %	-26.5%	76.9%	56%	71.4%	70.9%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	39.6%	39.9%	44.9%	46.7%	54.1%
EBITDA margin %	13.7%	17.6%	20.8%	22%	20.3%
EBIT margin %	13.7%	14.4%	16.9%	17.8%	14.6%
PAT margin %	10.2%	10%	11.7%	12.9%	9.6%
Working capital
Receivable days	—	83	102	99	117
Inventory days	—	188	230	190	280
Payable days	—	108	135	90	146
NWC days	—	162	197	200	251
Leverage
Current ratio	—	1.95	1.94	2.01	1.49
Debt to EBITDA	—	0.63	0.68	0.85	1.86
Debt to equity	—	0.14	0.15	0.2	0.32
Interest coverage	14	13.4	18.5	14.4	5.9
Asset turnover	—	0.87	0.72	0.73	0.52
Return ratios
Return on assets %	—	8.7%	8.4%	9.4%	5%
Return on capital employed %	—	17.2%	18%	18.7%	11.5%
Return on equity %	—	12.4%	12.3%	13.7%	8.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	46.3%	46.46%	46.46%	46.46%	46.1%	44.66%	44.29%	43.72%	42.88%	43.1%	43.08%	42.86%
	8.45%	8.16%	8.32%	7.06%	7.38%	8.64%	7.36%	7.35%	8.02%	7.68%	8.39%	8.17%
	10.51%	9.91%	9.97%	11.47%	11.35%	10.36%	7.53%	7.79%	6.96%	7.66%	7.41%	7.22%
	0%	0%	0%	0%	0%	0%	0%	0%	0.01%	0.01%	0.01%	0.01%
	34.74%	35.47%	35.25%	35.01%	35.17%	36.34%	40.82%	41.14%	42.13%	41.55%	41.11%	41.74%
No. of shareholders	—	—	—	—	—	—	—	—	1,90,655	1,84,489	1,79,373	1,76,506

Promoter holding down 3.44 percentage points since Sep 2023.

4 disclosures

Person	Deal	Shares	Value	Holding	Filed
Manjula Mahendra SangoiImmediate relative	SellMarket Sale	5,000	₹44.06 L	0.02% → 0.01%	26 Sept 20257(2)
SAFECHEM ENTERPRISES PRIVATE LIMITEDPromoter Group	SellMarket Sale	6,00,000	₹55.7 cr

36 deals · 3 Feb 2023 – 21 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
21 Sept 2026	UNIFI CAPITAL PRIVATE LIMITED	Bulk	NSE	Buy	9,15,000	₹820.00	₹75.03 Cr
18 Sept 2026	JASMINE FAMILY TRUST	Bulk	NSE	Sell	6,27,500	₹820.02	₹51.46 Cr
11 Aug 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Buy	7,17,028	₹903.94	₹64.82 Cr
11 Aug 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Sell	7,17,028	₹904.35	₹64.84 Cr
11 Aug 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	6,40,653	₹903.73	₹57.90 Cr
11 Aug 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	6,40,416	₹903.39	₹57.85 Cr
11 Aug 2026	QE SECURITIES LLP	Bulk	NSE	Buy	5,76,747	₹899.52	₹51.88 Cr
11 Aug 2026	QE SECURITIES LLP	Bulk	NSE	Sell	5,70,009	₹902.18	₹51.43 Cr
11 Aug 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	4,57,940	₹901.69	₹41.29 Cr
11 Aug 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	4,55,661	₹902.03	₹41.10 Cr

1–10 of 36

1 / 4

Mr. Rashesh Chandrakant GogriNon-Executive - Non Independent Director-Chairperson related to Promoter
Mrs. Hetal Gogri GalaExecutive Director-MD
Mr. Narendra Jagannath SalviExecutive Director-MD
Mr. Rajendra Vallabhaji GogriNon-Executive - Non Independent Director
Mr. Parimal Hasmukhlal DesaiNon-Executive - Non Independent Director
Mr. Vinay Gopal NayakNon-Executive - Independent Director
Mr. Bhavesh Rasiklal VoraNon-Executive - Independent Director
Mrs. Jeenal Kenil SavlaNon-Executive - Independent Director
Mrs. Rupal Anand VoraNon-Executive - Independent Director
Mr. Vilas Gajanan GaikarNon-Executive - Independent Director
Mr. Pradeep Hari Thakur

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

4

across 2 fund houses

Held by these funds

0.15%

of the company's equity

All mutual funds

0.79%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

4 schemes · 2 fund houses

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	1.34 L	11.3	0.45%	0.147%	-2,928
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	1,417	0.12	0.27%	0.002%	+2
IB18-Groww Nifty Total Market Index Fund	Groww Mutual Fund	915	0.08	0.02%	0.001%	+4
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	153	0.01	0.02%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

3

Credit ratings

1

Please find enclosed credit rating received from CRISIL Ratings Limited.17 Jul 2025 from CRISIL

Investor Presentation and earnings call

5

Aug 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

6

Final dividend15 Sept 2026 · ex-date₹2
Interim dividend16 Feb 2026 · ex-date₹1.5
Final dividend15 Sept 2025 · ex-date₹2.5
Interim dividend14 Feb 2025 · ex-date₹2.5
Final dividend31 Jul 2024 · ex-date₹1
Interim dividend16 Feb 2024 · ex-date₹2

1

Board meeting to consider results7 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

86 announcementsExport CSV

30 Sept 2026, 5:38 pmCompany Update

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

General PDF

30 Sept 2026, 11:00 amCompany Update

Intimation Under Regulation 30 Of SEBI Listing Regulations

General PDF

28 Sept 2026, 10:54 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

22 Sept 2026, 6:19 pmCompany Update

Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation PDF

22 Sept 2026, 5:26 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

2 Sept 2026, 8:29 pmCompany Update

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

General PDF

31 Aug 2026, 7:44 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

30 Aug 2026, 12:40 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
30 Sept 2026, 5:38 pm	Company Update General	Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015	PDF
30 Sept 2026, 11:00 am	Company Update General	Intimation Under Regulation 30 Of SEBI Listing Regulations

Loading announcements…

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

6

1

Announcements

Not in the F&O segment

6

1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends6

Board meetings1

Announcements

Not in the F&O segment

Dividends6

Board meetings1

Ratio timeline

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

6

1

6

1